Abbott gets nod for Xience Prime

Based on data from the SPIRIT family of trials, the FDA has given its OK for Abbott's ($ABT) next-generation Xience Prime everolimus-eluting stent system for the treatment of coronary artery disease.

Abbott says Xience Prime features a delivery system designed for greater flexibility and more accurate stent placement.

"With Xience Prime, for the first time in the U.S., physicians have a 38 mm everolimus-eluting stent for the treatment of long lesions. The enhanced deliverability and wide range of sizes, including a small-vessel 2.25 mm-diameter stent, will improve our ability to access challenging, complex lesions, and thereby improve care for our patients," explains Marco Costa, principal investigator of the global SPIRIT PRIME trial.

The system received CE Mark in 2009. It is now available in the U.S., Europe, the Middle East and most of Asia, according to an Abbott release.

As Mass Device notes, the clearance marks the latest round in the so-called stent wars between Abbott, Boston Scientific ($BSX) and Medtronic ($MDT).

- check out the Abbott statement
- get more from Mass Device

ALSO: Researchers are slated to discuss a flaw that causes drug-coated heart stents to weaken and shrink. The flaw, known as longitudinal compression, was added to the agenda at the Transcatheter Cardiovascular Therapeutics meeting that starts next week in San Francisco. News

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.